BIOEMTECH

BIOEMTECH is a high-tech company that offers innovative and at the same time affordable services and products in pharmaceutical and medical research. The company develops molecular imaging systems, provides services in Nuclear Medicine technology and has additional expertise on software medical solutions using AI techniques and MC simulations.

The company has developed the eyesTM desktop cameras for real-time in vivo imaging of SPECT and PET radionuclides and dyes. The eyesTM offer unmatched excellence in the challenging in vivo imaging of alpha emitters (Pb-212 & Ac-225) for oncological models, in short scanning times and clinically relevant doses.

BIOEMTECH laboratories are a rapidly growing CRO that offers a set of services related to preclinical research operating in a GLP environment. It covers a full chain of preclinical studies as follows: consulting and project management, in vitro testing, animal model development, radiochemical protocol development for a wide range of isotopes and 'cold' chemistry tests, non-invasive molecular imaging studies in small laboratory animals (multi-modal in vivo imaging studies: optical, PET, SPECT, CT), advanced image processing, clinical chemistry tests, drug efficacy studies , GLP toxicology studies, ex vivo biodistributions as well as postmortem analyses.

Both in BIOEMTECH’s services and products, fast screening applications are a core company value towards accelerating drug development. Finally, BIOEMTECH is active as an preclinical partner in several projects including H2020, Horizon Europe, FET, ERA, ITN and more.